SILVER SPRING
Mounjaro cleared for cardiovascular risk reduction in type 2 diabetes
- Sponsor
- Eli Lilly and Company $LLY
- Drug
- Mounjaro · tirzepatide
- Indication
- cardiovascular risk reduction in type 2 diabetes
FDA approved tirzepatide (Mounjaro) to lower cardiovascular risk in adults with type 2 diabetes.
What this means
Mounjaro is a weekly injection that treats type 2 diabetes by controlling blood sugar and appetite. The FDA has now also approved the drug to reduce the risk of major heart problems like heart attack and stroke in adults with type 2 diabetes and existing heart disease. This means patients already using Mounjaro for blood sugar control may receive the additional heart-protective benefit without needing a separate medication.
Drug Watch — recent news on Mounjaro
- Zepbound and Mounjaro may turn on the body’s calorie-burning brown fat - ScienceDaily
- GLP-1 companies face flurry of lawsuits after consumers say drugs caused vision loss - MassLive.com
- "They say not to use it during pregnancy..." Mounjaro prescribed to pregnant women in 325 cases - 스포츠조선
- I’m not obese but I’m taking Mounjaro for my health - The Telegraph
- Dear Doctor: Why do I keep getting pushed to increase a GLP-1 that's already working? - NJ.com
Sponsor Watch — recent news on Eli Lilly and Company
- Eli Lilly (LLY) vs. Novo Nordisk (NVO): Has the GLP-1 Race Changed the Moat?
- Eli Lilly (LLY) Wins Two FDA Approvals And A $3.35 Billion Drug Alliance
- Biotech Deal Week: Lilly, Novo And Novartis Pay Up For Platforms, Not Pipelines
- Sector Update: Healthcare Stocks Edge Higher Premarket Friday
- 91-year-old investor sees healthcare titan doubling in 3 years